Safety, Tolerability and Pharmacokinetic Study of HRS-8829

Summary

This study adopted a single-center, randomized, double-blind, placebo-controlled, dose-escalation design and was divided into three parts: single-dose dose-escalation (SAD) 、 multiple-dose dose-escalation (MAD)、drug-drug interaction（DDI）

Timeline

Start

2025-08-06

Primary completion

2026-01-12

Completion

2026-01-12

Drugs

Indications